Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus ConferencePRNewsWire · Oct 13, 2026
Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical TrialPRNewsWire · Oct 5, 2026
Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical TrialPRNewsWire · Oct 1, 2026
Anixa Biosciences (NASDAQ:ANIX) Stock: Insider Arnold Baskies Purchases 5,000 SharesDefense World · Sep 28, 2026
Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Buys $19,460.00 in StockDefense World · Sep 28, 2026
Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040PRNewsWire · Sep 21, 2026Anixa Biosciences, Inc. (ANIX) is a biotechnology company dedicated to pioneering therapies and vaccines. Its core mission revolves around addressing critical, unmet medical needs, particularly within the fields of oncology (cancer) and infectious diseases. Among its therapeutic pipeline, Anixa is developing a novel chimeric endocrine receptor T-cell (CER-T) technology, an innovative adaptation of CAR-T, specifically for ovarian cancer treatment.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 9, 2026 | -$0.08 | -$0.08 | Beat |
| Jun 10, 2026 | -$0.10 | -$0.07 | Beat |
| Mar 9, 2026 | -$0.09 | -$0.08 | Beat |
| Jan 12, 2026 | -$0.09 | -$0.09 | Miss |
| Sep 10, 2025 | -$0.10 | -$0.07 | Beat |
| May 28, 2025 | -$0.10 | -$0.09 | Beat |